In this issue of the journal, Schulz and colleagues present new data describing one-year outcomes from the ISAR-REACT 4 trial.
This study recruited patients undergoing PCI in the setting of a non-ST-elevation, acute coronary syndrome presentation. Subjects were randomised to two different periprocedural antithrombotic regimes: bivalirudin or combination therapy with unfractionated heparin (UFH) and abciximab. The reported rates of death, non-fatal myocardial infarction and target vessel revascularisation are near identical.
It is interesting to note that an increased risk of bleeding, observed at 30 days1, in patients receiving abciximab therapy, did not result in differences in key outcome measures at ...
Institute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
Sign in to read and download the full articleForgot your password?
No account yet? Sign up for free!Create my pcr account
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
Read next articleMore than ever, a true need to work together: Stent for Life